2023 World Conference on Lung Cancer (Posters)-EP13.01. Validation of LIPI index in SCLC

Pdf Summary

A multicenter retrospective study was conducted to validate the neutrophil-lymphocyte ratio (NLR) and the Lung Immune Prognostic Index (LIPI) in small cell lung carcinoma (SCLC) patients treated with 1L atezolizumab and chemotherapy. The study included 118 patients with a median age of 64 years. The majority of patients had low NLR and normal lactate dehydrogenase (LDH) levels.<br /><br />The overall survival (OS) was found to be 12.5 months, and the progression-free survival (PFS) was 5 months. The NLR and LDH levels did not have a significant impact on OS or PFS. However, there was a trend towards better OS with a baseline NLR of 3, but it did not reach statistical significance.<br /><br />The LIPI index, which classifies patients into three prognostic groups (LIPI 0, 1, or 2), did not show a significant impact on OS. However, it was associated with PFS, with LIPI-0 patients having a better PFS compared to LIPI-1 and LIPI-2 patients.<br /><br />The study suggests that the NLR, dNLR, and LDH level are not reliable prognostic or response factors in SCLC patients treated with 1L chemoimmunotherapy. On the other hand, the LIPI index, previously validated in non-small cell lung cancer (NSCLC), may be a prognostic factor that could be used in the future for SCLC patients.<br /><br />Further prospective studies are needed to investigate the association between LIPI and OS in SCLC patients. Overall, the study provides insights into the prognostic value of NLR and LIPI in SCLC patients undergoing 1L treatment with atezolizumab and chemotherapy.

Asset Subtitle

Ruth Alvarez Cabellos

Meta Tag

Speaker Ruth Alvarez Cabellos

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

multicenter study

neutrophil-lymphocyte ratio

Lung Immune Prognostic Index

small cell lung carcinoma

1L atezolizumab

chemotherapy

overall survival

progression-free survival

lactate dehydrogenase

prognostic factor